Literature DB >> 12835306

Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy.

N J Sebire1, S Haselden, M Malone, E G Davies, A D Ramsay.   

Abstract

Patients with primary immunodeficiencies such as the Wiskott-Aldrich syndrome (WAS) are prone to develop Epstein-Barr virus (EBV) related lymphoproliferative disorders (LPDs). EBV LPD is most frequently seen in patients receiving immunosuppressive treatment after organ transplantation (post-transplant lymphoproliferative disorder), but can also arise in the primary immunodeficiencies. Typically, EBV LPD presents as a diffuse systemic disease with lymphadenopathy and organ involvement. A rare angiocentric and angiodestructive form of EBV associated B cell LPD, lymphomatoid granulomatosis (LyG), has also been reported in association with WAS. LyG most commonly involves the lung, but can also be seen in brain, kidney, liver, and skin. This report describes the case of a 16 year old boy with WAS who presented with an isolated non-healing ulcerating skin lesion. Biopsy revealed an EBV related LPD with the histological features of LyG. This cutaneous lesion responded dramatically to treatment with specific anti-CD20 immunotherapy and the patient remains clinically free of LPD at 18 months.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12835306      PMCID: PMC1769998          DOI: 10.1136/jcp.56.7.555

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells.

Authors:  N Selenko; O Maidic; S Draxier; A Berer; U Jäger; W Knapp; J Stöckl
Journal:  Leukemia       Date:  2001-10       Impact factor: 11.528

2.  Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.

Authors:  N Milpied; B Vasseur; N Parquet; J L Garnier; C Antoine; P Quartier; A S Carret; D Bouscary; A Faye; B Bourbigot; Y Reguerre; A M Stoppa; P Bourquard; B Hurault de Ligny; F Dubief; A Mathieu-Boue; V Leblond
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

Review 3.  Lymphoproliferative disorders associated with congenital immunodeficiencies.

Authors:  K S Elenitoba-Johnson; E S Jaffe
Journal:  Semin Diagn Pathol       Date:  1997-02       Impact factor: 3.464

4.  Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.

Authors:  A H Filipovich; J V Stone; S C Tomany; M Ireland; C Kollman; C J Pelz; J T Casper; M J Cowan; J R Edwards; A Fasth; R P Gale; A Junker; N R Kamani; B J Loechelt; D W Pietryga; O Ringdén; M Vowels; J Hegland; A V Williams; J P Klein; K A Sobocinski; P A Rowlings; M M Horowitz
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  Defective expression of CD23 and autocrine growth-stimulation in Epstein-Barr virus (EBV)-transformed B cells from patients with Wiskott-Aldrich syndrome (WAS).

Authors:  H U Simon; E A Higgins; M Demetriou; A Datti; K A Siminovitch; J W Dennis
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

6.  High expression of MDM2 protein and low rate of p21(WAF1/CIP1) expression in SCID mice Epstein Barr virus-induced lymphoproliferation.

Authors:  S El Mansouri; A Martin; A Mercadier; C Capoulade; V Maréchal; J Wiels; J Feuillard; M Raphaël
Journal:  J Histochem Cytochem       Date:  1999-10       Impact factor: 2.479

7.  Intralesional rituximab for cutaneous B-cell lymphoma.

Authors:  T Paul; P Radny; S M Kröber; A Paul; H J Blaheta; C Garbe
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

Review 8.  Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview.

Authors:  K Iwatsuki; Z Xu; M Ohtsuka; F Kaneko
Journal:  J Dermatol Sci       Date:  2000-04       Impact factor: 4.563

9.  Posttransplant lymphoproliferative disorder: intrathoracic manifestations.

Authors:  G D Dodd; J Ledesma-Medina; R L Baron; C R Fuhrman
Journal:  Radiology       Date:  1992-07       Impact factor: 11.105

10.  Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt's lymphoma cells.

Authors:  J Rincon; J Prieto; M Patarroyo
Journal:  Int J Cancer       Date:  1992-05-28       Impact factor: 7.396

View more
  12 in total

1.  Angiocentric lesions of the head and neck.

Authors:  Cynthia M Magro; Molly Dyrsen
Journal:  Head Neck Pathol       Date:  2008-05-27

Review 2.  Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.

Authors:  Christopher Melani; Elaine S Jaffe; Wyndham H Wilson
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

Review 3.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

4.  Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature.

Authors:  Jayastu Senapati; Anup J Devasia; Sachin David; Marie Therese Manipadam; Sheila Nair; Giridhara R Jayandharan; Biju George
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

5.  Angiocentric immunoproliferative lesion and angiocentric lymphoma of lymph node in children. A report of two cases.

Authors:  R Drut; R M Drut
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

6.  Lymphomatoid granulomatosis with spinal involvement after childhood acute lymphoblastic leukemia.

Authors:  Insoo Kim
Journal:  Korean J Spine       Date:  2012-03-31

7.  The role of the innate immune system in granulomatous disorders.

Authors:  Helen J Petersen; Andrew M Smith
Journal:  Front Immunol       Date:  2013-05-24       Impact factor: 7.561

8.  Lymphomatoid granulomatosis treated successfully with rituximab in a renal transplant patient.

Authors:  Cindy Castrale; Wael El Haggan; Françoise Chapon; Oumedaly Reman; Thierry Lobbedez; Jean Philippe Ryckelynck; Bruno Hurault de Ligny
Journal:  J Transplant       Date:  2011-04-19

9.  Erythrodermic lymphomatoid granulomatosis: a case report.

Authors:  Kaoru Imaoka; Minao Furumura; Riruke Maruyama; Ren Nagasako; Eishin Morita
Journal:  Case Rep Dermatol       Date:  2011-11-30

10.  Lymphomatoid granulomatosis with splenomegaly and pancytopenia.

Authors:  Abolhasan Halvani; Mohammad Bagher Owlia; Ramin Sami
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.